535 related articles for article (PubMed ID: 10547583)
21. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
22. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
24. bcl-2 expression in pleural and extrapleural solitary fibrous tumours.
Chilosi M; Facchettti F; Dei Tos AP; Lestani M; Morassi ML; Martignoni G; Sorio C; Benedetti A; Morelli L; Doglioni C; Barberis M; Menestrina F; Viale G
J Pathol; 1997 Apr; 181(4):362-7. PubMed ID: 9196431
[TBL] [Abstract][Full Text] [Related]
25. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
Tigrani DY; Weydert JA
Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
[TBL] [Abstract][Full Text] [Related]
27. Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.
Bogers J; Jacobs W; Segers K; Van Daele A; Weyler J; Van Marck E
Pathol Res Pract; 1996 Jan; 192(1):10-4. PubMed ID: 8685035
[TBL] [Abstract][Full Text] [Related]
28. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
29. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
30. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
31. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
32. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
Gulyás M; Hjerpe A
J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
[TBL] [Abstract][Full Text] [Related]
33. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
34. Cadherins, catenins and APC in pleural malignant mesothelioma.
Abutaily AS; Collins JE; Roche WR
J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
[TBL] [Abstract][Full Text] [Related]
35. [Pleural mesothelioma: morphology, histochemistry, difficulties in diagnosis and nosologic problems (author's transl)].
Abelanet R; Jagueux M; Fondimare A; Roujeau J
Rev Fr Mal Respir; 1979; 7(3):243-64. PubMed ID: 91185
[TBL] [Abstract][Full Text] [Related]
36. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
Sington JD; Morris LS; Nicholson AG; Coleman N
Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
[TBL] [Abstract][Full Text] [Related]
37. Pleural sarcomatoid malignant mesothelioma consisting of histiocytoid cells.
Kawahara K; Nagano T; Matsui K; Kawai T; Iwasaki T
Pathol Int; 2007 Apr; 57(4):229-31. PubMed ID: 17316420
[No Abstract] [Full Text] [Related]
38. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
39. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
Shen J; Pinkus GS; Deshpande V; Cibas ES
Am J Clin Pathol; 2009 Apr; 131(4):516-23. PubMed ID: 19289587
[TBL] [Abstract][Full Text] [Related]
40. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
Clark SP; Chou ST; Martin TJ; Danks JA
J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]